World Bank Pharmaceuticals

Show simple item record

collection.link.221
https://openknowledge.worldbank.org/handle/10986/12995
collection.name.221
Health, Nutrition and Population (HNP) Discussion Papers
dc.contributor.author
Govindaraj, Ramesh
dc.contributor.author
Reich, Michael R.
dc.contributor.author
Cohen, Jillian C.
dc.date.accessioned
2013-06-04T19:31:08Z
dc.date.available
2013-06-04T19:31:08Z
dc.date.issued
2000-09
dc.date.lastModified
2021-04-23T14:03:10Z
dc.description.abstract
Pharmaceuticals have a major impact on health, on government and household spending, and on health systems. Despite the fundamental role of pharmaceuticals, there remains a profound gap between the benefit which pharmaceuticals have to offer and the reality that for millions of people -- particularly poor and disadvantaged people -- medicines are unavailable, unaffordable, unsafe or improperly used. This World Bank Pharmaceuticals Discussion Paper provides a pragmatic analysis of some of the causes for this gap and strategic directions to help close this gap. The strategic directions outlined in this Pharmaceuticals Discussion Paper complement and reinforce the objectives outlined in the WHO Medicines Strategy: 2000-2003 (World Health Organization, Geneva, 2000, WHO/EDM/2000.1). The WHO strategy describes specific objectives, expected outcomes, and progress indicators in the areas of drug policy, access to essential drugs, quality and safety, and rational use of medicines. Both the World Bank and the WHO initiatives rest on a fundamental commitment to work with governments, on governmental organizations, the private sector, professional bodies, and other key actors to help strengthen the pharmaceutical sector and its ability to contribute to improved health outcomes.. The current burden of disease falling on the two billion people living on less than one dollar per day undermines both individual well-being and collective economic development. Much of this burden of disease can be reduced by securing the availability, affordability, and rational use of essential drugs of assured quality. Yet this aim can not be achieved by governments alone, by individual multilateral organizations working alone, or by any other individual organization. It can only be achieved when committed governments and local organizations are supported by clear, consistency, and mutually compatible approaches by agencies such as the World Bank, WHO, UNICEF, others in the UN family, bilateral donors, and the broader development community. This discussion paper provides an important contribution to this process.
en
dc.identifier
http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals
dc.identifier.uri
http://hdl.handle.net/10986/13734
dc.language
English
dc.language.iso
en_US
dc.publisher
World Bank, Washington, DC
dc.relation.ispartofseries
HNP discussion paper series;
dc.rights
CC BY 3.0 IGO
dc.rights.holder
World Bank
dc.rights.uri
http://creativecommons.org/licenses/by/3.0/igo/
dc.subject
APPRAISAL REPORTS
dc.subject
BIDDING
dc.subject
CAPACITY BUILDING
dc.subject
CASE STUDY
dc.subject
CONTRACEPTIVES
dc.subject
CORRUPTION
dc.subject
COUNTERFEIT DRUGS
dc.subject
DECISION MAKING
dc.subject
DELIVERY SYSTEMS
dc.subject
DEVELOPED COUNTRIES
dc.subject
DEVELOPING COUNTRIES
dc.subject
DEVELOPING COUNTRY
dc.subject
DEVELOPMENT GOALS
dc.subject
DEVELOPMENT INDICATORS
dc.subject
DEVELOPMENT NETWORK
dc.subject
DEVELOPMENT PARTNERS
dc.subject
DEVELOPMENT STUDIES
dc.subject
DISTRIBUTION SYSTEMS
dc.subject
DRUG FINANCING
dc.subject
DRUG INDUSTRY
dc.subject
DRUG POLICY
dc.subject
DRUG SELECTION
dc.subject
ECONOMIC GROWTH
dc.subject
ECONOMICS
dc.subject
ESSENTIAL DRUGS
dc.subject
FINANCIAL SUPPORT
dc.subject
FORMAL POLICY
dc.subject
HEALTH CARE
dc.subject
HEALTH CARE PROVISION
dc.subject
HEALTH EXPENDITURES
dc.subject
HEALTH NEEDS
dc.subject
HEALTH OUTCOMES
dc.subject
HEALTH POLICY
dc.subject
HEALTH SECTOR
dc.subject
HEALTH WORKERS
dc.subject
HEPATITIS B
dc.subject
HOUSEHOLD INCOME
dc.subject
HUMAN CAPITAL
dc.subject
HUMAN DEVELOPMENT
dc.subject
IMPORTED DRUGS
dc.subject
IMPROVED HEALTH
dc.subject
INCOME COUNTRIES
dc.subject
INDIVIDUAL COUNTRIES
dc.subject
INSTITUTIONAL ANALYSIS
dc.subject
INTERNATIONAL MARKET
dc.subject
INTERVENTION
dc.subject
LOW-INCOME COUNTRIES
dc.subject
MALARIA
dc.subject
MANAGEMENT
dc.subject
MANAGEMENT CAPACITY
dc.subject
MANAGERS
dc.subject
MARKET FAILURES
dc.subject
MARKET INCENTIVES
dc.subject
MEDICAL SUPPLIES
dc.subject
MEDICINE
dc.subject
MEDICINES
dc.subject
MOTIVATION
dc.subject
NATIONAL DRUG POLICIES
dc.subject
NATIONAL DRUG POLICY
dc.subject
NATIONAL ESSENTIAL DRUG LISTS
dc.subject
NATIONAL ESSENTIAL DRUGS LISTS
dc.subject
NATIONAL POLICIES
dc.subject
NDP
dc.subject
NON- GOVERNMENTAL ORGANIZATIONS
dc.subject
NUTRITION
dc.subject
PARTNER INSTITUTIONS
dc.subject
PARTNERSHIP
dc.subject
PATENTS
dc.subject
PATIENTS
dc.subject
PHARMACEUTICAL COMPANIES
dc.subject
PHARMACEUTICAL FINANCING
dc.subject
PHARMACEUTICAL INDUSTRY
dc.subject
PHARMACEUTICAL MANUFACTURERS
dc.subject
PHARMACEUTICAL MARKETING
dc.subject
PHARMACEUTICAL MARKETS
dc.subject
PHARMACEUTICAL POLICIES
dc.subject
PHARMACEUTICAL POLICY
dc.subject
PHARMACEUTICAL PRICING
dc.subject
PHARMACEUTICAL PROCUREMENT
dc.subject
PHARMACEUTICAL PRODUCTION
dc.subject
PHARMACEUTICAL PRODUCTS
dc.subject
PHARMACEUTICAL REFORM
dc.subject
PHARMACEUTICAL REGULATORY AGENCIES
dc.subject
PHARMACEUTICAL SECTOR
dc.subject
PHARMACEUTICAL SUPPLY
dc.subject
PHARMACEUTICAL SYSTEMS
dc.subject
PHARMACEUTICAL WAREHOUSING
dc.subject
PHARMACEUTICALS
dc.subject
PHARMACIES
dc.subject
POLICY ANALYSIS
dc.subject
POLICY DIALOGUE
dc.subject
POLICY DOCUMENT
dc.subject
POLICY FRAMEWORK
dc.subject
POLICY IMPLICATIONS
dc.subject
POLICY PROCESS
dc.subject
PRICE COMPARISONS
dc.subject
PRIMARY HEALTH CARE
dc.subject
PRIVATE SECTOR
dc.subject
PRIVATE SECTORS
dc.subject
PROJECT IMPLEMENTATION
dc.subject
PUBLIC AGENCIES
dc.subject
PUBLIC HEALTH
dc.subject
PUBLIC POLICIES
dc.subject
PUBLIC POLICY
dc.subject
PUBLIC SECTOR
dc.subject
PURCHASING
dc.subject
QUALITY ASSURANCE
dc.subject
QUALITY CONTROL
dc.subject
RATIONAL USE OF DRUGS
dc.subject
SAFETY
dc.subject
SCHOOLS
dc.subject
SOCIAL MARKETING
dc.subject
STRUCTURAL ADJUSTMENT
dc.subject
TASK TEAM LEADERS
dc.subject
TECHNICAL ASSISTANCE
dc.subject
THERAPIES
dc.subject
VACCINES
dc.subject
WIDESPREAD CORRUPTION
dc.subject
WORKERS PHARMACEUTICALS
dc.subject
BURDEN OF DISEASE
dc.subject
HEALTH CARE SYSTEMS
dc.subject
MULTILATERAL ORGANIZATIONS
dc.subject
HEALTH CARE
dc.subject
HEALTH CARE FINANCE
dc.subject
HEALTH CARE FINANCING
dc.subject
HEALTH SYSTEMS DEVELOPMENT & REFORM
dc.title
World Bank Pharmaceuticals
en
okr.doctype
Publications & Research :: Working Paper
okr.doctype
Publications & Research
okr.docurl
http://documents.worldbank.org/curated/en/2000/09/3928594/world-bank-pharmaceuticals
okr.globalpractice
Poverty
okr.googlescholar.linkpresent
yes
okr.identifier.externaldocumentum
000265513_20040603124203
okr.identifier.internaldocumentum
3928594
okr.identifier.report
28876
okr.language.supported
en
okr.pdfurl
http://www-wds.worldbank.org/external/default/WDSContentServer/WDSP/IB/2004/06/03/000265513_20040603124203/Rendered/PDF/288760Govindar1Pharmacuetical1whole.pdf
en
okr.topic
Health Monitoring and Evaluation
okr.topic
Pharmaceuticals and Pharmacoeconomics
okr.topic
Health Economics and Finance
okr.topic
Pharmaceuticals Industry
okr.topic
Poverty Reduction :: Poverty Assessment
okr.unit
Health, Nutrition & Popultn Team (HDNHE)
okr.volume
1 of 1

Show simple item record



This item appears in the following Collection(s)